Prelude Therapeutics' (PRLD) Restructuring is Great News - Citizens

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $3.00 price target on Prelude Therapeutics (NASDAQ: PRLD).

The analyst commented, "We reiterate our Market Outperform rating and our $3 price target for Prelude Therapeutics based on a platform and cash/share analysis. Yesterday, Prelude reported 3Q25 earnings and reiterated a sharpened pipeline focus on JAK2V617F and KAT6A targets as well as a $60MM exclusive option deal with Incyte (INCY, MP). We view this restructuring as great news for shareholders as it marks a decisive shift to a focused strategy targeting high-value, clinically-validated assets with clear paths to differentiation. With both programs expected to enter the clinic in 2026 and a pro forma cash position of $124.3MM, we believe Prelude shares represent an attractive investment opportunity."

For an analyst ratings summary and ratings history on Prelude Therapeutics click here. For more ratings news on Prelude Therapeutics click here.

Shares of Prelude Therapeutics closed at $1.51 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Tilly's, Inc. (TLYS) Tops Q1 EPS by 44c ; offer guidance
• BTIG Upgrades Medtronic, Inc. (MDT) to Buy